These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 27654854)

  • 1. Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure.
    Felker GM; Mentz RJ; Cole RT; Adams KF; Egnaczyk GF; Fiuzat M; Patel CB; Echols M; Khouri MG; Tauras JM; Gupta D; Monds P; Roberts R; O'Connor CM
    J Am Coll Cardiol; 2017 Mar; 69(11):1399-1406. PubMed ID: 27654854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload.
    Konstam MA; Kiernan M; Chandler A; Dhingra R; Mody FV; Eisen H; Haught WH; Wagoner L; Gupta D; Patten R; Gordon P; Korr K; Fileccia R; Pressler SJ; Gregory D; Wedge P; Dowling D; Romeling M; Konstam JM; Massaro JM; Udelson JE;
    J Am Coll Cardiol; 2017 Mar; 69(11):1409-1419. PubMed ID: 28302292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials.
    Felker GM; Mentz RJ; Adams KF; Cole RT; Egnaczyk GF; Patel CB; Fiuzat M; Gregory D; Wedge P; O'Connor CM; Udelson JE; Konstam MA
    Circ Heart Fail; 2015 Sep; 8(5):997-1005. PubMed ID: 26374918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.
    Gheorghiade M; Konstam MA; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Cook T; Ouyang J; Zimmer C; Orlandi C;
    JAMA; 2007 Mar; 297(12):1332-43. PubMed ID: 17384438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
    Gheorghiade M; Gattis WA; O'Connor CM; Adams KF; Elkayam U; Barbagelata A; Ghali JK; Benza RL; McGrew FA; Klapholz M; Ouyang J; Orlandi C;
    JAMA; 2004 Apr; 291(16):1963-71. PubMed ID: 15113814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
    Konstam MA; Gheorghiade M; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Cook T; Ouyang J; Zimmer C; Orlandi C;
    JAMA; 2007 Mar; 297(12):1319-31. PubMed ID: 17384437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).
    Gheorghiade M; Orlandi C; Burnett JC; Demets D; Grinfeld L; Maggioni A; Swedberg K; Udelson JE; Zannad F; Zimmer C; Konstam MA
    J Card Fail; 2005 May; 11(4):260-9. PubMed ID: 15880334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Tolvaptan Addition to Furosemide in Normo- and Hyponatremia Patients with Heart Failure and Chronic Kidney Disease Stages G3b-5: A Subanalysis of the K-STAR Study.
    Tominaga N; Kida K; Inomata T; Sato N; Izumi T; Akashi YJ; Shibagaki Y
    Am J Nephrol; 2017; 46(5):417-426. PubMed ID: 29130954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study).
    Matsuzaki M; Hori M; Izumi T; Fukunami M;
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S33-45. PubMed ID: 22120092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial.
    Ambrosy AP; Khan H; Udelson JE; Mentz RJ; Chioncel O; Greene SJ; Vaduganathan M; Subacuis HP; Konstam MA; Swedberg K; Zannad F; Maggioni AP; Gheorghiade M; Butler J
    Circ Heart Fail; 2016 May; 9(5):. PubMed ID: 27140204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-Hospital Diuretic Agent Use and Post-Discharge Clinical Outcomes in Patients Hospitalized for Worsening Heart Failure: Insights From the EVEREST Trial.
    Mecklai A; Subačius H; Konstam MA; Gheorghiade M; Butler J; Ambrosy AP; Katz SD
    JACC Heart Fail; 2016 Jul; 4(7):580-588. PubMed ID: 27039131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
    Greene SJ; Gheorghiade M; Vaduganathan M; Ambrosy AP; Mentz RJ; Subacius H; Maggioni AP; Nodari S; Konstam MA; Butler J; Filippatos G;
    Eur J Heart Fail; 2013 Dec; 15(12):1401-11. PubMed ID: 23845795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Tolvaptan in Patients More Than 90 Years Old With Acute Heart Failure.
    Sato Y; Uzui H; Mukai M; Shiomi Y; Hasegawa K; Ikeda H; Tama N; Fukuoka Y; Morishita T; Ishida K; Kaseno K; Miyazaki S; Nakano A; Tada H
    J Cardiovasc Pharmacol Ther; 2020 Jan; 25(1):47-56. PubMed ID: 31280620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolvaptan add-on therapy and its effects on efficacy parameters and outcomes in patients hospitalized with heart failure.
    Kansara T; Gandhi H; Majmundar M; Kumar A; Patel JA; Kokkirala A; Moskovits N; Mushiyev S; Basman C
    Indian Heart J; 2022; 74(1):40-44. PubMed ID: 34919966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Tolvaptan in patients with acute heart failure: a systematic review and meta-analysis.
    Wang C; Xiong B; Cai L
    BMC Cardiovasc Disord; 2017 Jun; 17(1):164. PubMed ID: 28633650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The efficacy and safety of tolvaptan on treating heart failure patients with hyponatremia].
    Li L; Bai H; Zhu WL;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):936-40. PubMed ID: 22321279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study.
    Matsue Y; Suzuki M; Nagahori W; Yoshida K; Onishi Y; Satoh Y; Ono Y; Nishioka T; Noda M; Sugi K; Torii S; Tejima T; Sakurada H; Yamaguchi S; Okishige K; Fujii H; Takahashi A
    Cardiovasc Drugs Ther; 2014 Feb; 28(1):73-7. PubMed ID: 24048511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of tolvaptan on volume overload in Japanese patients with heart failure: results of a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Matsuzaki M; Hori M; Izumi T; Asanoi H; Tsutamoto T;
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S19-31. PubMed ID: 22120091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics of responders to treatment with tolvaptan in patients with acute decompensated heart failure: Importance of preserved kidney size.
    Toda H; Nakamura K; Nakahama M; Wada T; Watanabe A; Hashimoto K; Terasaka R; Tokioka K; Nishii N; Miyoshi T; Kohno K; Kawai Y; Miyaji K; Koide Y; Tachibana M; Yoshioka R; Ito H;
    J Cardiol; 2016 Feb; 67(2):177-83. PubMed ID: 26072263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction.
    Matsue Y; Ter Maaten JM; Suzuki M; Torii S; Yamaguchi S; Fukamizu S; Ono Y; Fujii H; Kitai T; Nishioka T; Sugi K; Onishi Y; Noda M; Kagiyama N; Satoh Y; Yoshida K; van der Meer P; Damman K; Voors AA; Goldsmith SR
    Clin Res Cardiol; 2017 Oct; 106(10):802-812. PubMed ID: 28540483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.